Clinical trials: sponsored by The Netherlands Cancer Institute
Ovarian Cancer
Clinical Impact of Dedicated MR Staging of Ovarian Cancer
The only chance of cure for patients with advanced stage ovarian cancer is complete cytoreductive surgery (CRS). The only way to determine whether complete CRS can be achieved is by a laparoscopy.
- Trial name
- MRStagingOC (NCT03399344)
- Testing
- MRI
- Where
- Netherlands
- Volunteers
- 270 people
- Sponsor
- The Netherlands Cancer Institute
Renal Cell Carcinoma
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
a monocenter, open label, single arm, phase II study of the combination of axitinib with avelumab as neoadjuvant therapy in patients with intermediate to high-risk non-metastatic RCC.
- Trial name
- NCT03341845
- Testing
- Axitinib, Avelumab
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Neoplasms
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
In this study it will be determined whether the rate of severe toxicity associated with fluoropyrimidine treatment (capecitabine or 5-fluorouracil) can be significantly diminished by individualized dosing of fluoropyrimidines…
- Trial name
- NCT02324452
- Testing
- Fluoropyrimidine (capecitabine or 5-fluorouracil)
- Where
- 17 sites in Netherlands
- Volunteers
- 1,103 people
- Sponsor
- The Netherlands Cancer Institute
Non-Small Cell Lung Cancer
Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
Concurrent chemoradiotherapy is the standard treatment for locally advanced non-small cell lung carcinoma (NSCLC). Different chemotherapy and radiation regimens have been advocated but in general, cisplatin-doublets are deemed…
- Trial name
- HYPOLAN (NCT02947113)
- Testing
- Cisplatin, hypofractionated radiotherapy, Pemetrexed
- Sponsor
- The Netherlands Cancer Institute
NSCLC
PET Response During Chemoradiation of Lung Cancer
A prospective observational study to determine the prognostic value of the timing of 50% reduction in metabolic activity (T50) during CCRT for NSCLC for treatment outcome (PFS).
- Trial name
- NCT02315053
- Testing
- Low dose FDG PET/CT 5 x.
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Cancer
The Effectiveness of Patient Navigation in Cancer Care
Rationale: Supportive care such as physical therapy, psycho-social education, and dietary advice is likely to have a positive effect on the recovery and quality of life of cancer patients.
- Trial name
- NCT03305965
- Testing
- Patient navigation
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer, DNA
Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation
Rationale: Understanding the mechanisms of enzalutamide as an androgen receptor inhibitor in early prostate cancer could lead to improved patient selection for treatment.
- Conditions
- Prostate Cancer, DNA, Androgen Receptor Abnormal
- Trial name
- DARANA (NCT03297385)
- Testing
- Enzalutamide
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Esophageal Cancer
4D FDG PET in Esophageal Cancer
FDG PET-CT image acquisition in the abdominal and thoracic region is influenced by organ motion. Respiratory movement blurs the metabolic signal of the esophageal tumor and lymph nodes.
- Trial name
- NCT02424864
- Testing
- 4d PET-CT
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer
Background: The Dutch guideline on breast cancer treatment shows several grey areas, where no clear recommendation is given on the radiotherapy options, but where the advice is to discuss the treatment of choice with the patient.
- Trial name
- M16SDM (NCT02934126)
- Testing
- breast cancer patients
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Radiation Therapy Followed by Surgery in Treating Patients With Early-Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving CT-guided accelerated radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
- Trial name
- PAPBI (NCT01024582)
- Testing
- biopsy, fine-needle aspiration, accelerated partial breast irradiation
- Where
- Netherlands
- Volunteers
- 139 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Melanoma
Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients
This is a Phase 2 trial consisting of 24 patients receiving the combination of dabrafenib + trametinib + pembrolizumab in 3 different dosing schemes and 8 patients receiving pembrolizumab standard monotherapy.
- Trial name
- IMPemBra (NCT02625337)
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Carcinoma, Non-Small-Cell Lung
Lung Cancer Early Molecular Assessment Trial
The investigators hypothesize that an early molecular profiling, that includes both tissue and blood-bases analysis, for all NSCLC patients, including stage I-III, will increase diagnostic efficiency.
- Trial name
- LEMA (NCT02894853)
- Testing
- Liquid (blood) biopsies and tumor biopsy (optional)
- Where
- Netherlands
- Volunteers
- 1,297 people
- Sponsor
- The Netherlands Cancer Institute
Malignant Pleural Mesothelioma
Nivolumab in Patients With Recurrent Malignant Mesothelioma
This is a prospective, single arm, phase II trial in previously treated patients with MPM who are considered candidates for immunotherapy and repeat thoracoscopies/transthoracic biopsies.
- Trial name
- NivoMes (NCT02497508)
- Testing
- nivolumab
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment.
- Trial name
- NCT00684216
- Testing
- capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Pharmacokinetics of Pazopanib
Study With Improved Solubility Pazopanib
The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.
- Trial name
- NCT02810756
- Testing
- New Pazopanib formulation
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Cocaine Addiction
Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots
The pharmacokinetics of 10 to 12 individuals receiving 60 mg of sustained release dexamphetamine will be studied. These individuals have received this medication before in a previous trial where the pharmacodynamics were…
- Trial name
- NCT02768441
- Testing
- Dexamphetamine
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Malignant Pleural Mesothelioma
Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma
- Trial name
- N08CPA (NCT01211275)
- Testing
- axitinib, chemotherapy
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- The Netherlands Cancer Institute
Breast Neoplasms, Cardiovascular Diseases
Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors
The purpose of this study is to evaluate the prevalence of (sub)clinical cardiovascular disease, cardiovascular risk factors and metabolic abnormalities among long-term breast cancer survivors treated with or without…
- Trial name
- HARBOR (NCT02485626)
- Testing
- 2D tissue doppler echocardiography
- Where
- 2 sites in Netherlands
- Volunteers
- 628 people
- Sponsor
- The Netherlands Cancer Institute
Sarcoma,Soft Tissue
Combined Modality Treatment of Sarcomas of the Extremities
In this study, we aim to define the recommended dose of a VEGFR-TKI (pazopanib) in combination with RT pre-operatively given.
- Trial name
- PASART-1 (NCT01985295)
- Testing
- pazopanib
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan vs placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab.
- Trial name
- NCT00459771
- Testing
- AT1 blocker candesartan
- Where
- 19 sites in Netherlands
- Volunteers
- 210 people
- Sponsor
- The Netherlands Cancer Institute